Abstract: The invention relates to a probe (110, 210, 310, 410, 510) which has a sealed cooling chamber (140, 240, 340, 440, 540) arranged within a casing (112, 212, 312, 412, 512) of the probe. An interface unit (124, 224, 324, 424, 524) of the probe is at least partially arranged within the cooling chamber or in contact with the cooling chamber. The cooling chamber is at least partially filled with a heat transfer liquid (142, 242, 342, 442, 542).

Abstract: A probe, in particular for ultrasound, having a cooling chamber which is fluidtight and at least partially filled with a dielectric heat-transfer fluid. An interface unit associated with an emitting and/or receiving element of the probe is located at least partially inside or in contact with the cooling chamber. The probe includes a dry chamber separated from the cooling chamber by a fluidtight wall, and a porous heat sink arranged at least partially inside the cooling chamber.

Abstract: This application relates to compounds of Formula (I): [targeting peptide]-N(R1)—X1(R2)L1-[linker]-RXn1 (I). The targeting peptide is cyclo[L-Phe-L-Tyr-L-Lys(iPr)-D-Arg-L-2-Nal-Gly-D-Glu]-L-Lys(iPr). R1 is H or methyl. X1 is an optionally substituted C1-C15 hydrocarbon optionally comprising heteroatoms. R2 is C(O)OH or C(O)NH2. L1 is a linkage (thiolether, amide, maleimide-thiol, triazole). The linker has a net negative charge at physiological pH and is a linear or branched chain of 1-10 units of X2L2 and/or X2(L2)2, wherein: each X2 is, independently, an optionally substituted C1-C15 hydrocarbon optionally comprising heteroatoms; and each L2 is a linkage. The linker optionally further comprises an albumin binder bonded to an L2. Each RX is a radiolabelling group linked through a separate L2, selected from: a metal chelator; a prosthetic group containing trifluoroborate (BF3); or a prosthetic group containing a silicon-fluorine-acceptor moiety.

Abstract: The invention relates to a probe (110, 210, 310, 410, 510) which has a sealed cooling chamber (140, 240, 340, 440, 540) arranged within a casing (112, 212, 312, 412, 512) of the probe. An interface unit (124, 224, 324, 424, 524) of the probe is at least partially arranged within the cooling chamber or in contact with the cooling chamber. The cooling chamber is at least partially filled with a heat transfer liquid (142, 242, 342, 442, 542).

Abstract: There is provided bombesin-derived compounds of Formula Ia (RX-L-Xaa1-Gln-Trp-Ala-Val-Xaa2-His-Xaa3-?-Xaa4-NH2). RX comprises a radionuclide chelator or a trifluoroborate-containing prosthetic group. L is a linker. Xaa1 is D-Phe, Cpa (4-chlorophenylalanine), D-Cpa, Tpi (2,3,4,9-tetrahydro-1H-pyrido[3,4b]indol-3-carboxylic acid), D-Tpi, Nal (naphthylalanine), or D-Nal. Xaa2 is Gly, N-methyl-Gly or D-Ala. Xaa3 is Leu, Pro, D-Pro, or Phe. Xaa4 is Pro, Phe, Tac (thiazolidine-4-carboxylic acid), Nle (norleucine), 4-oxa-L-Pro (oxazolidine-4-carboxylic acid). The symbol ? represents a reduced peptide bond between Xaa3 and Xaa4 in which ? is CH2—N when Xaa4 is Pro, Tac or 4-oxa-L-Pro, or ? is CH2N(R) when Xaa4 is Phe or Nle wherein R is H or C1-C5 linear or branched alkyl. There is also provided the use of such compounds as imaging agents or therapeutic agents.